ESMO 2019 - Results from #120

Viewing 121-138 of 138 articles

ESMO 2019: ENTRATA: Randomized, Double-Blind, Phase 2 Study of Telaglenastat + Everolimus vs. Placebo + Everolimus in Patients with Advanced/Metastatic Renal Cell Carcinoma

ESMO 2019: BISCAY: An Adaptive, Biomarker Directed Platform Study in Metastatic Urothelial Cancer with Durvalumab in Combination with Targeted Therapies

ESMO 2019: Docetaxel for Hormone-Naïve Prostate Cancer: Results from Long-Term Follow-Up of Metastatic (M1) Patients in the STAMPEDE Randomized Trial and Sub Group Analysis by Metastatic Burden - Medical Oncologist Perspective

ESMO 2019: Adjuvant or Salvage Radiotherapy for the Treatment of Localized Prostate Cancer? A Prospectively Planned Aggregate Data Meta-Analysis - A Medical Oncologist's Perspective

ESMO 2019: Timing of Radiotherapy after Radical Prostatectomy: First Results from the RADICALS Radiation Therapy Randomised Controlled Trial

ESMO 2019: Invited Discussant - An Update on the Phase 3 SPARTAN Study and Long-term Outcomes for M1 Patients in the STAMPEDE Randomized Trial - A Medical Oncologist's Perspective

ESMO 2019: Invited Discussant - An Update on the Phase 3 SPARTAN Study and Long-term Outcomes for M1 Patients in the STAMPEDE Randomized Trial

ESMO 2019: Apalutamide and Overall Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Updated Results From the Phase 3 SPARTAN Study

ESMO 2019: RADICALS and ARTISTIC Discussion: Thoughts from a Radiation Oncologist

ESMO 2019: Timing of Radiotherapy After Radical Prostatectomy: First Results from the RADICALS Radiotherapy Randomized Controlled Trial

ESMO 2019: Treatment Intensification in Advanced Prostate Cancer: SPARTAN, STAMPEDE, and Others

ESMO 2019: Adjuvant or Salvage Radiotherapy for the Treatment of Localized Prostate Cancer? A Prospectively Planned Aggregate Data Meta-analysis

ESMO 2019: Docetaxel for Hormone-naïve Prostate Cancer: Results from Long-term Follow-up of Metastatic Patients in the STAMPEDE Randomized Trial and Sub-group Analysis by Metastatic Burden

New Data for BAVENCIO® (avelumab) for Advanced Cancers To Be Presented at ESMO 2019

ESMO 2019: Updated Results from the Phase 3 SPARTAN Study, Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (apalutamide)

Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019

Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019

1
2
3
4
5
6
7